Master’s degree from the University of Economics in Kraków, major in Management and Marketing (1994). A graduate of the University of Copenhagen, major in Business Relations Management (1992). D’Orsay Academy of Gastronomy and Wine 1990. From
Read moreSenior Scientific Advisor, Immunotherapy and Co-founder. Prof. Golab heads the Department of Immunology at the Medical University of Warsaw (MUW), where he manages a group of 40 researchers and thus far promoted 14 PhD students. His
Read moreDr. Douglas W.P. Hay obtained his PhD in Physiology and Pharmacology from the University of Strathclyde, Scotland. Douglas is a Pharmaceutical Executive with more than 20 years in Drug Discovery, with particular expertise in respiratory and
Read moreDr. Adam Gołębiowski, who is a co-founder of Molecure brings over 20 years of experience in leading research and development and drug discovery programs. In 1987 he completed his doctorate at the Institute of Organic Chemistry
Read moreMarcin has over 15 years of experience in technology transfer, R&D project and life science investment management. He has been involved in preparation and management of more than 40 R&D and investment projects with a combined
Read more- Significant partnership agreement with the world-renowned International Institute of Molecular and Cell Biology in Warsaw (IIMCB) to accelerate the strategic development of OncoArendi’s small molecule RNA platform - Novel dual acting first-in-class arginase inhibitor OATD-02
Read more- Option to in-license and develop small molecule leads against a novel target for the treatment of fibrotic diseases - Strengthens pipeline and reinforces OncoArendi’s strategic focus on fibrotic diseases including idiopathic pulmonary fibrosis (IPF) 11
Read moreNew members to bring additional scientific, operational and HR expertise Warsaw, Poland – 31 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal capabilities to
Read moreDr. Fung to Lead Global Clinical Development, Translational Science and Regulatory Strategies Warsaw, Poland – 27 January 2022 - OncoArendi Therapeutics S.A. (”OncoArendi”; WSE: OAT), a clinical stage biotechnology company that uses its world leading medicinal
Read more
